Researcher

Guonan Zhang

Sichuan Cancer Hospital

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 18, 2026 · JOURNAL ARTICLE

Serplulimab combined with bevacizumab and chemotherapy as first-line treatment for recurrent or metastatic cervical cancer (ASTRUM-CC01): a phase II trial

Frontiers in Immunology

Single-arm phase II trial showing encouraging ORR and PFS in a small cohort, but lacks a control arm and mature OS data; results warrant phase III confirmation but do not yet change practice.

PromisingGuonan Zhang Chunyan Wang Hong Liu

Reported

Sample size evaluable43

Objective response rate75.00%

ORR 95% CI60.40–86.36

AUG 18, 2026 · JOURNAL ARTICLE

Real-world efficacy and safety profile of low-dose cadonilimab in recurrent or metastatic cervical cancer as first-line therapy

Frontiers in Immunology

A real-world retrospective study of adequate size showing encouraging efficacy (ORR 55.6%, 12-month OS 92.1%) with manageable toxicity in R/M cervical cancer, but lacking a control arm and requiring prospective validation.

Promising石训为 Can Zhang Guonan Zhang

Reported

Sample size (efficacy-evaluable)133

Primary endpoint: Objective Respo…55.6%

Disease Control Rate83.5%